16th World Clinical Biomarkers & CDx Summit
Recent advancements in liquid biopsy-driven MRD detection, high-plex single-cell and multi-omic profiling, alongside next-generation innovations in digital pathology, spatial analytics, and IVD assays, are propelling precision medicine into a defining new phase.
Fueled by this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit makes its return to Boston, with our largest and most comprehensive program to date.
Convening 850+ senior stakeholders from biopharma, diagnostic, regulatory, healthcare, testing labs, and multimodal organizations, this forum remains the touchpoint for those looking to inform the next step in progressing drug-diagnostic programs from bench to bedside.
See the all-new event program with sessions spanning biomarker discovery, diagnostic imaging, genomics, multi-omics, and AI-driven innovation.
To reflect how the field is moving today, we have reworked the agenda to include brand-new data-driven case studies, additional networking, enhanced stakeholder perspectives, and five tracks of content.
For the first time, gain insights from:
- AI & Tech Innovators: Hear how AWS, Google Cloud, and Microsoft are innovating cutting-edge AI and advanced compute to harness omics, digital imaging, and multimodal data to deliver compliant, scalable, insight-ready intelligence.
- Precision Oncology Associations & Charities: Learn how BLOODPAC, Precision Cancer Consortium and TargetCancer Foundation are accelerating calls-to-arms in testing, R&D innovation, standardization, and equitable access, ensuring harmonized approvals, launches, and adoption of drug-diagnostics.
- Non-Oncology Biopharma Pioneers: Discover how novel biomarkers and advances in non-invasive multimodal IVD assays are elevating the standards of care and enabling earlier detection with Alexion Pharmaceuticals, Novartis, and PTC Therapeutics.
With complimentary* passes available for biopharma teams with active, publicly disclosed pipelines, seize your chance to unite with peers, align on next-generation biomarker strategies, and ensure your drug-diagnostic programs are primed for continued clinical and commercial success.
Attendance is FREE* for qualifying biopharma and researchers.
*Subject to terms and conditions: Visit the website to learn more.
